Panacea Acquisition Quote - NUVB

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.4099

Bid

Ask

Volume

512,919

2.40 Day's Range 2.54

1.52 52 Week Range 4.1598

Market Cap

811.092M

Previous Close

2.42

Open

2.48

Last Trade

2.4088

Last Trade Time

11:29:41

Financial Volume

US$ 1,264,190

VWAP

2.4647

Average Volume (3m)

2,668,037

Shares Outstanding

336,566,525

Dividend Yield

PE Ratio

-10.75

Earnings Per Share (EPS)

-0.23

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was US$2.42. Over the last year, Panacea Acquisition shares have traded in a share price range of US$ 1.52 to US$ 4.1598.

Panacea Acquisition currently has 336,566,525 shares outstanding. The market capitalization of Panacea Acquisition is US$814.49 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -10.75.

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Taletrectinib will be marketed in China by Innovent Biologics Approval is based on the pivotal Phase 2 TRUST-I study, demonstrating taletrectinib's durable responses and prolonged...

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free...

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire SAN FRANCISCO and SUZHOU, China, Dec. 20...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.3601	-13	2.77	2.82	2.391	1964520	2.47822389	CS
4	-0.2101	-8.01908396947	2.62	3.455	2.391	2988583	2.74168022	CS
12	-0.1601	-6.22957198444	2.57	3.455	2.391	2668037	2.75611568	CS
26	-1.1901	-33.0583333333	3.6	3.97	2	2015539	2.72527076	CS
52	0.6699	38.5	1.74	4.1598	1.52	1749485	2.8301414	CS
156	-3.3901	-58.45	5.8	6.23	0.95	1133709	2.68624865	CS
260	-7.5901	-75.901	10	15.23	0.95	1071682	4.17678974	CS

NUVB - Frequently Asked Questions (FAQ)

What is the current Panacea Acquisition share price?

The current share price of Panacea Acquisition is US$ 2.4099

How many Panacea Acquisition shares are in issue?

Panacea Acquisition has 336,566,525 shares in issue

What is the market cap of Panacea Acquisition?

The market capitalisation of Panacea Acquisition is USD 814.49M

What is the 1 year trading range for Panacea Acquisition share price?

Panacea Acquisition has traded in the range of US$ 1.52 to US$ 4.1598 during the past year

What is the PE ratio of Panacea Acquisition?

The price to earnings ratio of Panacea Acquisition is -10.75

What is the reporting currency for Panacea Acquisition?

Panacea Acquisition reports financial results in USD

What is the latest annual profit for Panacea Acquisition?

The latest annual profit of Panacea Acquisition is USD -75.8M

What is the registered address of Panacea Acquisition?

The registered address for Panacea Acquisition is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Panacea Acquisition website address?

The website address for Panacea Acquisition is ecor1cap.com

Which industry sector does Panacea Acquisition operate in?

Panacea Acquisition operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DMDesktop Metal Inc	US$ 2.585 (19.12%)	348.72k
OSKOshkosh Corporation	US$ 113.30 (18.48%)	943.61k
BFLYButterfly Network Inc	US$ 4.15 (18.23%)	9.67M
FLGFlagstar Financial Inc	US$ 11.265 (17.34%)	9.28M
CCMConcord Medical Services Holdings Ltd	US$ 4.99 (14.98%)	39.11k
MSBMesabi Trust	US$ 24.21 (-28.44%)	188.52k
WHRWhirlpool Corp	US$ 106.95 (-17.59%)	3.12M
UPSUnited Parcel Service	US$ 111.835 (-16.40%)	24.88M
NOWServiceNow Inc	US$ 998.675 (-12.67%)	3.56M
COURCoursera Inc	US$ 8.375 (-12.58%)	2.2M
QBTSD Wave Quantum Inc	US$ 5.865 (6.25%)	37.72M
NOKNokia Corp	US$ 4.7584 (7.17%)	37.48M
NUNu Holdings Ltd	US$ 13.41 (6.85%)	33.42M
BBAIBigBear ai Holdings Inc	US$ 4.135 (13.60%)	30.09M
BBDBanco Bradesco SA	US$ 2.095 (4.75%)	26.76M